
FDA Warns of Growing Threat From ‘Gas Station Heroin' Sold as Supplements
Federal health officials are warning about a surge in reports of serious health issues tied to tianeptine, a drug being sold as a supplement despite not being approved for any medical use in the United States.
Commonly referred to as 'gas station heroin' due to its availability at convenience stores, gas stations, and online retailers, tianeptine has been associated with overdoses, withdrawal symptoms, and at least one cluster of deaths. The Food and Drug Administration (FDA) issued a renewed alert this week, urging the public and health care providers to avoid products that contain the substance.
'I am writing to draw your attention to a dangerous and growing health trend facing our nation and particularly young people—the increasing number of adverse events involving products containing tianeptine, which can lead to serious harm, including death,' FDA Commissioner Dr. Martin Makary said in a May 8
The FDA stressed that many consumers mistakenly
The drug is prescribed as an antidepressant in some countries, though it is not approved in the United States and is not scheduled under the Controlled Substances Act. The FDA notes that it is being illegally sold as a dietary supplement or 'nootropic,' with product names that include Tianaa, Zaza, Neptune's Fix, Pegasus, and TD Red.
Some vendors are also making unproven and illegal claims that tianeptine can improve brain function or treat anxiety, depression, pain, and opioid use disorder, according to the agency.
Related Stories
4/23/2025
4/22/2025
Ingesting tianeptine can lead to severe health effects, including respiratory depression, coma, and death. Withdrawal symptoms similar to those caused by opioids have also been reported. Medical literature cites instances of users taking doses of up to 10,000 milligrams per day—hundreds of times greater than the level it is prescribed at in other countries.
The FDA noted that individuals with a history of opioid dependence may be particularly vulnerable to abusing tianeptine, sometimes using it as an opioid substitute or for self-treatment of mental health conditions.
A 2024 outbreak in New Jersey linked to a product called 'Neptune's Fix' highlighted the drug's dangers. The product was found to contain both tianeptine and synthetic cannabinoid receptor agonists, the agency said. Reported side effects included seizures, cardiac irregularities, and fatalities.
'Historically, there has been a delayed recognition of fast-growing trends, such as opioid abuse and vaping addiction in youth,' Makary said in the statement. 'Let's be proactive in understanding and addressing the use of tianeptine products, which are available even to our nation's youth.'
The FDA has taken some enforcement actions, including issuing warning letters and placing imports of tianeptine-containing products on alert to prevent them from entering the country. Still, the agency noted that the products continue to be sold without regulation.
The agency also classified tianeptine as an unsafe food additive and stated it does not meet the legal definition of a dietary ingredient, underscoring that such products cannot be lawfully marketed as supplements.
Health care professionals are being advised to counsel patients on avoiding tianeptine and to consider alternative, evidence-based treatments for conditions such as depression, anxiety, or opioid use disorder. In cases of suspected tianeptine poisoning, medical professionals should contact the Poison Help Line and report incidents to the FDA's MedWatch portal.
The FDA emphasized that routine drug screening panels may not detect tianeptine, complicating diagnosis in emergency settings.
Consumers and medical professionals can report adverse effects or suspicious products through the FDA's website or by calling 1-888-INFO-FDA. Individuals struggling with substance use or addiction can call 1-800-662-HELP or visit FindTreatment.gov for support and treatment resources.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


News24
an hour ago
- News24
Joburg woman finishes epic N1 walk to Cape Town for husband's rare disease 10 days early
Nicole Liedemann-Telukram completed her 1 400km walk from Johannesburg to Cape Town 10 days ahead of schedule, raising awareness and funds for her husband Shaun's rare condition, Dercum's disease. Supported throughout the journey by her best friend, Paballo, in a safety vehicle and her trusty boerboel, Zaza, Nicole described the journey as physically and emotionally transformative, highlighting the mental endurance required and the generosity of South Africans along the way. The campaign has raised R15 000 so far, and Nicole remains committed to fighting for rare disease research and funding, saying, 'This is just the start.' Nicole Liedemann-Telukram has completed her 1 400km walk from Johannesburg to Cape Town, 10 days ahead of schedule. Just over a month ago, Nicole decided to embark on a journey along the N1 to raise awareness and funds for her husband Shaun Telukram's rare disease, called Dercum's disease. She documented the trip on TikTok and directed followers to her fundraising platforms. - See Nicole's BackaBuddy page More than a month after starting the walk, she arrived in sunny Cape Town to take a photo at the famous V&A Waterfront sign. Her journey was not without difficulties. A pulled hamstring just after Lainsburg and the physical demands of walking the Huguenot Tunnel tested her endurance. One of the most physically taxing parts of her journey was near Colesberg when she battled blisters and the flu. 'My body felt like it was giving up on me,' Nicole told News24 in Cape Town. 'When you are walking, it's only yourself and your thoughts. I don't walk with earphones in; it's just myself and the road. Your mind gets to you, where you feel self-doubt, but you have to pull yourself towards yourself and remind yourself the reason why you are doing it.' While the first leg of the journey began with excitement, the second half became more difficult. 'It's not just about Dercum's, it's about so many things,' she said. Nicole expressed deep gratitude for the support of her best friend, Paballo, who accompanied her by car for the entire journey for safety and her trusty boerboel, Zaza. 'Paddy, my sister, my best friend, motivator, Swiss Army knife, master of all... I could not be more grateful. I don't think there are enough words to describe how blessed I was to have had her on this journey. Yes, I was walking, but I could not have done it without her.' Supplied/Neo Paballo-Mahao Because the pair remained vigilant, they generally felt safe on their journey. One hair-raising moment came in Paarl, where they heard that a body had been found nearby. This did not deter them: 'There was a task that needed to be completed, a personal task, a mental task, an emotional task, a physical task. And yes, we completed it. I'm still in awe.' Kind South Africans and the plight goes on Nicole arrived in Cape Town last week with a deep sense of fulfilment. 'I sat there in silence with a big smile on my face. We did it. I actually did it. When you do something out of your comfort zone and succeed, it takes you back a little. I was filled with emotion, excitement and fulfilment.' READ | Joburg woman halfway through N1 walk to Cape Town, beating blisters, blessed by strangers Messages of pride and congratulations from family and friends continue to pour in. 'I hope I reached the people I needed to. The people we spoke to along the way made it all worthwhile. Mentally, I'm okay – I haven't processed everything yet, but I'm still extremely positive and optimistic.' The campaign has so far raised around R15 000 and Nicole is determined to continue her fundraising efforts and search for sponsors, as they aim to reach R200 000. Dr Karen Herbst, one of the leading Dercum's researchers in the world, based in the US, also got in touch to amplify Nicole's efforts. 'We did not raise too much, but my plight has not stopped. I'm still continuing to raise awareness and funds. We didn't raise much at all, but it doesn't take away from the reason why I did this and why I am still going to continue to fight for a rare disease and for my husband.' Rare disease research is underfunded. We need chemical pathologists to do the work, but we also need the funding. My mission is not complete yet. Reflecting on the experience, Nicole said the journey was unforgettable. 'South Africa is a beautiful place. People in small towns are kind and generous. The trucking community became our cocoon of safety. We stayed at truck stops. There are so many people I want to thank. There are a lot of amazing people in this country.' 'This is just the start.'
Yahoo
3 hours ago
- Yahoo
Recall alert: Over 19,000 cans of Dr Pepper Zero Sugar recalled for containing sugar
Over 19,000 cases of Dr Pepper Zero Sugar are being recalled after the cans were found to contain full-sugar soda, the U.S. Food and Drug Administration announced. The voluntary recall issued on May 23 affects the 12-ounce aluminum cans of a 12-pack and 24-pack case of Dr Pepper Zero Sugar. 'Product labeled to be zero sugar contains full sugar product,' the FDA wrote about the drink. The recalled product contains the same amount of sugar found in regular Dr Pepper, which is 39 grams per can. The recalled cans have the product code XXXXRS05165 with a 'best by' date of February 16, 2026. The cans were made by Pepsi Beverages Company in Jacksonville, Florida and distributed to only Florida, Georgia and South Carolina. On June 5, the FDA then classified the product as a class II recall. This level of recall is 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote,' according to the FDA. See the full recall here. Recall alert: These window air conditioners could cause mold exposure Recall alert: Bring these crackers back to the store due to undeclared allergen Recall alert: Throw away these 17 salads, salsas due to salmonella concern Read the original article on MassLive.
Yahoo
3 hours ago
- Yahoo
Parents are dismayed after FDA rejects experimental drug 4-year-old girl relies on
A family thought they had a life-changing drug for their 4-year-old daughter. Then the FDA rejected it. Channel 2's Michael Doudna heard from the girl's parents. For Hope Filchak, her daily routine includes a daily shot to help provide a normal life. However, soon the drug may go away. 'It's scary to think she might not have this in just a few months,' Caroline Filchak, Hope's mother, said. [DOWNLOAD: Free WSB-TV News app for alerts as news breaks] Hope was born with a rare mitochondrial disease that impacts fewer than 100 people in the world. The impacts are wide-ranging and a challenge to overcome. 'From early on, it was an uphill battle for Hope,' Caroline Filchak said. 'I think she's got 12 specialists that we see in three different states.' 'It affects her brain, her heart, her eyes and her ears, deafness, blindness, and then two heart defects,' Ben Filchak, Hope's father, said. There are no FDA-approved drugs for Hope's condition. So when heart troubles arose in 2024, the family was forced to turn to an experimental drug, elemipretide, and saw immediate improvement. 'Her energy increased, and her heart function has stabilized completely,' Ben Fiilchak said. However, last month, the FDA declined to give it approval. 'I would say that the FDA is trying to regulate two things, right. They're trying to make sure the products are safe, including drugs, but also that they are efficacious for people,' said Rossana Sanchez Russo, an Emory clinical geneticist. According to the parent company producing the drug, the FDA's rejection was in part because the FDA did not see an improvement in a six-minute walk test. 'We all know in the field that a six-minute walk test is not the be-all end-all outcome measure for mitochondrial diseases,' Amy Goldstein, a leading mitochondrial disease expert, said. She says the drug showed improvement in areas such as quality of life and cardiac health. 'I myself personally saved a baby in my cardiac ICU with Barre syndrome. He went home with no cardiac manifestations after arriving here in severe heart failure and needing a heart transplant,' Goldstein said. 'We were extremely disappointed that based on all of the data, they made the decision not to approve the drug.' Another hurdle rare disease drug testing faces is sample size. By its very nature, only a few people have these diseases, so getting a meaningful sample during clinical trials can be difficult. 'Sometimes we don't have enough burden of proof to be able to formally say that. That doesn't mean that it may not be working for a family or that it might not work for other conditions. It may mean that we just do not have all the data,' Sanchez Russo said. The FDA says the company behind the drug can reapply for approval, but it is unclear if it will be successful and how long the company can stay committed to producing a drug without the FDA giving an OK. Hope's family has a four-month supply of the drug left. However, they do not know how much longer access to the medicine will last. 'Hope is a special little girl, and she means so much to our family,' Caroline Filchak said. TRENDING STORIES: Raids uncover largest fentanyl pill operation in state history in Atlanta, Douglasville Hurricane season starts quietly in the Atlantic They were once best friends, then one killed the other. We take you inside this bizarre murder case [SIGN UP: WSB-TV Daily Headlines Newsletter]